Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low-dose regimens

Pediatric Blood and Cancer

Volumn 57, Issue 6, 2011, Pages 1029-1033

  Lin, Pei Chin ^a,b   Liao, Yu Mei ^a,b   Tsai, Shih Pien ^a   Chang, Tai Tsung ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Bypass therapy; FVIII inhibitor; Hemophilia A; Immune tolerance induction (ITI)

Indexed keywords

AZATHIOPRINE; BLOOD CLOTTING FACTOR 8 INHIBITOR; METHOTREXATE; PREDNISOLONE; STEROID;

ADOLESCENT; ANTIBODY TITER; ARTICLE; CANCER RELAPSE; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONSTIPATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEMOPHILIA A; HUMAN; IMMUNE TOLERANCE INDUCTION THERAPY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFANT; LOW DRUG DOSE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; INFANT; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052660511     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23291     Document Type: Article

References (42)

1. Oldenburg J, Dolan G, Lemm G. Haemophilia care then, now and in the future. Haemophilia 2009; 15: 2-7.
2. Berntorp E, Shapiro A, Astermark J, et al. Inhibitor treatment in haemophilias a and b: Summary statement for the 2006 international consensus conference. Haemophilia 2006; 12: 1-7.
3. Lusher JM, Arkin S, Abildgaard CF, et al. Recombinant factor viii for the treatment of previously untreated patients with hemophilia a. Safety, efficacy, and development of inhibitors. Kogenate previously untreated patient study group. N Engl J Med 1993; 328: 453-459.
4. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia a: A systematic review. Haemophilia 2003; 9: 418-435.
5. Dimichele D. Immune tolerance therapy for factor viii inhibitors: Moving from empiricism to an evidence-based approach. J Thromb Haemost 2007; 5: 143-150.
6. Brackmann HH, Gormsen J. Massive factor viii infusion in a haemophiliac with factor viii inhibitor, high responder (letter). Lancet 1977; 2: 933.
7. Brackmann HH. Induced immunotolerance in factor viii inhibitor patients. Prog Clin Biol Res 1984; 150: 181-195.
8. Aznar JA, Jorquera JI, Peiro A, et al. The imporatnce of corticoids added to continued treatment with factor viii concentrates in the suppression of inhibitors in haemophilia a. Thromb Haemost 1984; 51: 217-221.
9. Ewing NP, Sanders NL, Dietrich SL, et al. Induction of immune tolenrance to factor viii in haemophiliacs with inhibitors. JAMA 1988; 259: 65-68.
10. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendall G, et al. Low dose immune tolerance induction in haemophilia a patients with inhibitors. Blood 1995; 86: 983-988.
11. DiMichele DM. Immune tolerance: Critical issues of factor dose, purity and treatment complications. Haemophilia 2006; 12: 81-85; discussion 85-86.
12. Paisley S, Wight J, Currie E, et al. The management of inhibitors in haemophilia a: Introduction and systematic review of current practice. Haemophilia 2003; 9: 405-417.
13. Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia a with inhibitors: A systematic review. Haemophilia 2003; 9: 436-463.
14. Lenk H. The german registry of immune tolerance treatment in hemophilia-1999 update. Haematologica 2000; 85: 45-47.
15. Aznar JA, Abad-Franch L, Cortina VR, et al. The national registry of haemophilia a and b in spain: Results from a census of patients. Haemophilia 2009; 15: 1327-1330.
16. Iorio A, Oliovecchio E, Morfini M, et al. Italian registry of haemophilia and allied disorders. Objectives, methodology and data analysis. Haemophilia 2008; 14: 444-453.
17. Barnes C, Rivard GE, Poon MC, et al. Canadian multi-institutional survey of immune tolerance therapy (itt)-Experience with the use of recombinant factor viii for itt. Haemophilia 2006; 12: 1-6.
18. Dimichele D. The north american immune tolerance registry: Contributions to the thirty-year experience with immune tolerance therapy. Haemophilia 2009; 15: 320-328.
19. Ghirardini A, Puopolo M, Chiarotti F, et al. The international registry of immune tolerance: 1994 update. Vox Sang 1996; 70: 42-46.
20. Dimichele DM, Hoots WK, Pipe SW, et al. International workshop on immune tolerance induction: Consensus recommendations1. Haemophilia 2007; 13: 1-22.
21. Soucie JM, Cianfrini C, Janco RL, et al. Joint range-of-motion limitations among young males with hemophilia: Prevalence and risk factors. Blood 2004; 103: 2467-2473.
22. Hay CR, Brown S, Collins PW, et al. The diagnosis and management of factor viii and ix inhibitors: A guideline from the united kingdom haemophilia centre doctors organisation. Br J Haematol 2006; 133: 591-605.
23. Aledort LM. Factor viii inhibitor bypassing activity (feiba)-Addressing safety issues. Haemophilia 2008; 14: 39-43.
24. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor viia. JAMA 2006; 295: 293-298.
25. Abshire T, Kenet G. Safety update on the use of recombinant factor viia and the treatment of congenital and acquired deficiency of factor viii or ix with inhibitors. Haemophilia 2008; 14: 898-902.
26. Dimichele D. Inhibitors to factor viii-epidemiology and treatment. In: Lee CA, Berntorp EE, Hoots WK, editors. Textbook of hemophilia. Malden: Blackwell Publishing Ltd; 2005. pp 64-70.
27. Schwaab R, Brackmann HH, Meyer C, et al. Haemophilia a: Mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-1406.
28. Millar DS, Steinbrecher RA, Wieland K, et al. The molecular genetic analysis of haemophilia a; characterization of six partial deletions in the factor viii gene. Hum Genet 1990; 86: 219-227.
29. Oldenburg J, Schroder J, Brackmann HH, et al. Environmental and genetic factors influencing inhibitor development. Semin Hematol 2004; 41: 82-88.
30. Oldenburg J, Tuddenham E. Genetic basis of inhibitor development in severe haemophilia a and b. In: Rodriguez-Merchan EC, Lee CA, Inhibitors in patients with haemophilia. Oxford: Blackwell Science; 2002. pp 21-26.
31. Lavigne-Lissalde G, Schved JF, Granier C, et al. Anti-factor viii antibodies: A 2005 update. Thromb Haemost 2005; 94: 760-769.
32. Sultan Y, Kazatchkine MD, Maisonneuve P, et al. Anti-idiotypic suppression of autoantibodies to factor viii (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; 2: 765-768.
33. Sakurai Y, Shima M, Tanaka I, et al. Association of anti-idiotypic antibodies with immune tolerance induction for the treatment of hemophilia a with inhibitors. Haematologica 2004; 89: 696-703.
34. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with haemophilia and antibodies to factor viii by combined treatment with intravenous igg, cyclophosphamide and factor viii. N Engl J Med 1988; 318: 947-950.
35. Hay C, Goldberg I, Foulkes M, et al. International prospective randomised immune tolerance (iti) study: Interim analysis of therapeutic efficacy and safety. Haemophilia 2010; 16: Abstract 17P36, 73.
36. Kroner BL. Comparison of the international immune tolerance registry and the north american immune tolerance registry. Vox Sang 1999; 77: 33-37.
37. Punnonen J, Aversa G, Cocks BG, et al. Interleukin 13 induces interleukin 4-independent igg4 and ige synthesis and cd23 expression by human b cells. Proc Natl Acad Sci USA 1993; 90: 3730-3734.
38. Saint-Remy JM. Hemophilia factor viii therapy. B- and t-cell tolerance: From basic concepts to clinical practice. Haematologica 2000; 85: 93-96.
39. Qian J, Borovok M, Bi L, et al. Inhibitor antibody development and t cell response to human factor viii in murine hemophilia a. Thromb Haemost 1999; 81: 240-244.
40. Van den Berg HM, Fischer K. Prophylaxis. In: Lee CA, Berntorp EE, Hoots WK, editors. Textbook of hemophilia. Malden: Blackwell Publishing Ltd; 2005. pp 39-45.
41. Fischer K, Astermark J, van der Bom JG, et al. Prophylactic treatment for severe haemophilia: Comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002; 8: 753-760.
42. Gouw SC, van der Bom JG, Marijke van den Berg H, et al. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia a: The canal cohort study. Blood 2007; 109: 4648-4654.